Immunological corollary of the pulmonary mycobiome in bronchiectasis

the CAMEB study

Micheál Mac Aogáin, Ravishankar Chandrasekaran, Albert Yick Hou Lim, Teck Boon Low, Gan Liang Tan, Hassan Tidi Maharani, Thun How Ong, Amanda Hui Qi Ng, Denis Bertrand, Jia Yu Koh, Sze Lei Pang, Zi Yang Lee, Xiao Wei Gwee, Christopher Martinus, Yang Yie Sio, Sri Anusha Matta, Fook Tim Chew, Holly R. Keir, John E. Connolly, John Arputhan Abisheganaden & 4 others Mariko Siyue Koh, Niranjan Nagarajan, James D. Chalmers, Sanjay H. Chotirmall

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Understanding the composition and clinical importance of the fungal mycobiome was recently identified as a key topic in a "research priorities" consensus statement for bronchiectasis.Patients were recruited as part of the CAMEB study: an international multicentre cross-sectional Cohort of Asian and Matched European Bronchiectasis patients. The mycobiome was determined in 238 patients by targeted amplicon shotgun sequencing of the 18S-28S rRNA internally transcribed spacer regions ITS1 and ITS2. Specific quantitative PCR for detection of and conidial quantification for a range of airway Aspergillus species was performed. Sputum galactomannan, Aspergillus specific IgE, IgG and TARC (thymus and activation regulated chemokine) levels were measured systemically and associated to clinical outcomes.The bronchiectasis mycobiome is distinct and characterised by specific fungal genera, including Aspergillus, Cryptococcus and ClavisporaAspergillus fumigatus (in Singapore/Kuala Lumpur) and Aspergillus terreus (in Dundee) dominated profiles, the latter associating with exacerbations. High frequencies of Aspergillus-associated disease including sensitisation and allergic bronchopulmonary aspergillosis were detected. Each revealed distinct mycobiome profiles, and associated with more severe disease, poorer pulmonary function and increased exacerbations.The pulmonary mycobiome is of clinical relevance in bronchiectasis. Screening for Aspergillus-associated disease should be considered even in apparently stable patients.

Original languageEnglish
JournalThe European respiratory journal
Volume52
Issue number1
DOIs
Publication statusPublished - 1 Jul 2018

Fingerprint

Bronchiectasis
Aspergillus
Lung
Chemokine CCL17
Allergic Bronchopulmonary Aspergillosis
Cryptococcus
Singapore
Firearms
Sputum
Immunoglobulin E
Lung Diseases
Multicenter Studies
Mycobiome
Immunoglobulin G
Polymerase Chain Reaction
Research

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Immunological corollary of the pulmonary mycobiome in bronchiectasis : the CAMEB study. / Mac Aogáin, Micheál; Chandrasekaran, Ravishankar; Lim, Albert Yick Hou; Low, Teck Boon; Tan, Gan Liang; Tidi Maharani, Hassan; Ong, Thun How; Hui Qi Ng, Amanda; Bertrand, Denis; Koh, Jia Yu; Pang, Sze Lei; Lee, Zi Yang; Gwee, Xiao Wei; Martinus, Christopher; Sio, Yang Yie; Matta, Sri Anusha; Chew, Fook Tim; Keir, Holly R.; Connolly, John E.; Abisheganaden, John Arputhan; Koh, Mariko Siyue; Nagarajan, Niranjan; Chalmers, James D.; Chotirmall, Sanjay H.

In: The European respiratory journal, Vol. 52, No. 1, 01.07.2018.

Research output: Contribution to journalArticle

Mac Aogáin, M, Chandrasekaran, R, Lim, AYH, Low, TB, Tan, GL, Tidi Maharani, H, Ong, TH, Hui Qi Ng, A, Bertrand, D, Koh, JY, Pang, SL, Lee, ZY, Gwee, XW, Martinus, C, Sio, YY, Matta, SA, Chew, FT, Keir, HR, Connolly, JE, Abisheganaden, JA, Koh, MS, Nagarajan, N, Chalmers, JD & Chotirmall, SH 2018, 'Immunological corollary of the pulmonary mycobiome in bronchiectasis: the CAMEB study', The European respiratory journal, vol. 52, no. 1. https://doi.org/10.1183/13993003.00766-2018
Mac Aogáin, Micheál ; Chandrasekaran, Ravishankar ; Lim, Albert Yick Hou ; Low, Teck Boon ; Tan, Gan Liang ; Tidi Maharani, Hassan ; Ong, Thun How ; Hui Qi Ng, Amanda ; Bertrand, Denis ; Koh, Jia Yu ; Pang, Sze Lei ; Lee, Zi Yang ; Gwee, Xiao Wei ; Martinus, Christopher ; Sio, Yang Yie ; Matta, Sri Anusha ; Chew, Fook Tim ; Keir, Holly R. ; Connolly, John E. ; Abisheganaden, John Arputhan ; Koh, Mariko Siyue ; Nagarajan, Niranjan ; Chalmers, James D. ; Chotirmall, Sanjay H. / Immunological corollary of the pulmonary mycobiome in bronchiectasis : the CAMEB study. In: The European respiratory journal. 2018 ; Vol. 52, No. 1.
@article{441ec2fd572b468c8898f4d91c1c62a0,
title = "Immunological corollary of the pulmonary mycobiome in bronchiectasis: the CAMEB study",
abstract = "Understanding the composition and clinical importance of the fungal mycobiome was recently identified as a key topic in a {"}research priorities{"} consensus statement for bronchiectasis.Patients were recruited as part of the CAMEB study: an international multicentre cross-sectional Cohort of Asian and Matched European Bronchiectasis patients. The mycobiome was determined in 238 patients by targeted amplicon shotgun sequencing of the 18S-28S rRNA internally transcribed spacer regions ITS1 and ITS2. Specific quantitative PCR for detection of and conidial quantification for a range of airway Aspergillus species was performed. Sputum galactomannan, Aspergillus specific IgE, IgG and TARC (thymus and activation regulated chemokine) levels were measured systemically and associated to clinical outcomes.The bronchiectasis mycobiome is distinct and characterised by specific fungal genera, including Aspergillus, Cryptococcus and ClavisporaAspergillus fumigatus (in Singapore/Kuala Lumpur) and Aspergillus terreus (in Dundee) dominated profiles, the latter associating with exacerbations. High frequencies of Aspergillus-associated disease including sensitisation and allergic bronchopulmonary aspergillosis were detected. Each revealed distinct mycobiome profiles, and associated with more severe disease, poorer pulmonary function and increased exacerbations.The pulmonary mycobiome is of clinical relevance in bronchiectasis. Screening for Aspergillus-associated disease should be considered even in apparently stable patients.",
author = "{Mac Aog{\'a}in}, Miche{\'a}l and Ravishankar Chandrasekaran and Lim, {Albert Yick Hou} and Low, {Teck Boon} and Tan, {Gan Liang} and {Tidi Maharani}, Hassan and Ong, {Thun How} and {Hui Qi Ng}, Amanda and Denis Bertrand and Koh, {Jia Yu} and Pang, {Sze Lei} and Lee, {Zi Yang} and Gwee, {Xiao Wei} and Christopher Martinus and Sio, {Yang Yie} and Matta, {Sri Anusha} and Chew, {Fook Tim} and Keir, {Holly R.} and Connolly, {John E.} and Abisheganaden, {John Arputhan} and Koh, {Mariko Siyue} and Niranjan Nagarajan and Chalmers, {James D.} and Chotirmall, {Sanjay H.}",
year = "2018",
month = "7",
day = "1",
doi = "10.1183/13993003.00766-2018",
language = "English",
volume = "52",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "1",

}

TY - JOUR

T1 - Immunological corollary of the pulmonary mycobiome in bronchiectasis

T2 - the CAMEB study

AU - Mac Aogáin, Micheál

AU - Chandrasekaran, Ravishankar

AU - Lim, Albert Yick Hou

AU - Low, Teck Boon

AU - Tan, Gan Liang

AU - Tidi Maharani, Hassan

AU - Ong, Thun How

AU - Hui Qi Ng, Amanda

AU - Bertrand, Denis

AU - Koh, Jia Yu

AU - Pang, Sze Lei

AU - Lee, Zi Yang

AU - Gwee, Xiao Wei

AU - Martinus, Christopher

AU - Sio, Yang Yie

AU - Matta, Sri Anusha

AU - Chew, Fook Tim

AU - Keir, Holly R.

AU - Connolly, John E.

AU - Abisheganaden, John Arputhan

AU - Koh, Mariko Siyue

AU - Nagarajan, Niranjan

AU - Chalmers, James D.

AU - Chotirmall, Sanjay H.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Understanding the composition and clinical importance of the fungal mycobiome was recently identified as a key topic in a "research priorities" consensus statement for bronchiectasis.Patients were recruited as part of the CAMEB study: an international multicentre cross-sectional Cohort of Asian and Matched European Bronchiectasis patients. The mycobiome was determined in 238 patients by targeted amplicon shotgun sequencing of the 18S-28S rRNA internally transcribed spacer regions ITS1 and ITS2. Specific quantitative PCR for detection of and conidial quantification for a range of airway Aspergillus species was performed. Sputum galactomannan, Aspergillus specific IgE, IgG and TARC (thymus and activation regulated chemokine) levels were measured systemically and associated to clinical outcomes.The bronchiectasis mycobiome is distinct and characterised by specific fungal genera, including Aspergillus, Cryptococcus and ClavisporaAspergillus fumigatus (in Singapore/Kuala Lumpur) and Aspergillus terreus (in Dundee) dominated profiles, the latter associating with exacerbations. High frequencies of Aspergillus-associated disease including sensitisation and allergic bronchopulmonary aspergillosis were detected. Each revealed distinct mycobiome profiles, and associated with more severe disease, poorer pulmonary function and increased exacerbations.The pulmonary mycobiome is of clinical relevance in bronchiectasis. Screening for Aspergillus-associated disease should be considered even in apparently stable patients.

AB - Understanding the composition and clinical importance of the fungal mycobiome was recently identified as a key topic in a "research priorities" consensus statement for bronchiectasis.Patients were recruited as part of the CAMEB study: an international multicentre cross-sectional Cohort of Asian and Matched European Bronchiectasis patients. The mycobiome was determined in 238 patients by targeted amplicon shotgun sequencing of the 18S-28S rRNA internally transcribed spacer regions ITS1 and ITS2. Specific quantitative PCR for detection of and conidial quantification for a range of airway Aspergillus species was performed. Sputum galactomannan, Aspergillus specific IgE, IgG and TARC (thymus and activation regulated chemokine) levels were measured systemically and associated to clinical outcomes.The bronchiectasis mycobiome is distinct and characterised by specific fungal genera, including Aspergillus, Cryptococcus and ClavisporaAspergillus fumigatus (in Singapore/Kuala Lumpur) and Aspergillus terreus (in Dundee) dominated profiles, the latter associating with exacerbations. High frequencies of Aspergillus-associated disease including sensitisation and allergic bronchopulmonary aspergillosis were detected. Each revealed distinct mycobiome profiles, and associated with more severe disease, poorer pulmonary function and increased exacerbations.The pulmonary mycobiome is of clinical relevance in bronchiectasis. Screening for Aspergillus-associated disease should be considered even in apparently stable patients.

UR - http://www.scopus.com/inward/record.url?scp=85052907816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052907816&partnerID=8YFLogxK

U2 - 10.1183/13993003.00766-2018

DO - 10.1183/13993003.00766-2018

M3 - Article

VL - 52

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 1

ER -